What does the future hold for cell-based assays in pharma? Visiongain’s report shows you potential revenues and other trends, with data, forecasts and discussions.
Our study analyses products and services for cell-based testing. It covers activities of product developers and pre-clinical contract research organisations.
You discover sales predictions to 2022 at world market, main submarket and national levels. Find potential revenues for products and services.
Also, you receive discussions of many companies in the cell assay industry, seeing their activities and outlooks.
Companies featured include the following:
• BD Biosciences
• Life Technologies
• Beckman Coulter
• GE Healthcare
• Thermo Fisher Scientific
• Charles River Laboratories
• MD Biosciences.
Looking ahead to 2022, many commercial opportunities exist for cell-based testing. Our report gives you business research and analysis there.
Where are cellular assays heading? Greater need for cellular information earlier in pre-clinical product development stimulates demand for the tests. Our report shows you how their use is increasing in drug discovery and development.
Which developmental processes will benefit most from cell assays? This decade, drug screening and toxicity testing will be important applications for cell-based products and services, our analysis shows.
At present, half of all assays used in pharmaceutical development are cell-based. Miniaturisation and automation are important. We find wide scope for developing the systems and applications from 2012 to 2022, seeing many opportunities.
What are the limitations of cell-based assays? For their potential to be achieved, challenges must be tackled. Systems such as 3D assays will allow for more-accurate simulation of in vivo conditions in cell cultures. Our report explains.
Visiongain’s study provides data, analysis and opinion aiming to benefit your research, calculations and presentations. You find answers now in our work.
Revenue forecasts, market shares, developmental trends and discussions
In our report you find revenue forecasting, growth rates and market shares. Also, you have qualitative analyses (SWOT and STEP) and discussion of technologies, existing and in development. You receive 74 tables and charts and two research interviews.
Advantages of Cell-Based Assays: World Market Prospects 2012-2022 for your work
In particular, this study gives you the following knowledge:
• Find potential revenues to 2022 for the world market and submarkets
• See market forecasting to 2022 for US, Japan, EU5, China and India
• Assess leading companies, discovering activities and outlooks
• Review technological developments, assessing trends and prospects
• Investigate competition and opportunities influencing revenues
• Find out what will stimulate and restrain the industry and market
• Analyse pharma R&D spending by stage and find an overall forecast to 2022
• View opinions from our survey, receiving detailed interviews.
There, you find a distinctive mix of quantitative and qualitative analyses with independent predictions. Without our report, you could miss out on information that your competitors are using.
We analyse developments and prospects in cellular testing, helping you to stay ahead.
Gain business research and analysis for cell-based assays
Our study is for everybody needing industry and market analyses for cell assays. Find data, trends and answers. Avoid missing out – please order our report now.
For more information kindly visit :
Cell-Based Assays: World Market Prospects 2012-2022
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Follow us on twitter: http://twitter.com/#!/Sandhya3B